Please login to the form below

Not currently logged in
Email:
Password:

Lupin appoints European president

Maurice Chagnaud moves to India-based company from Teva

India-based Lupin has appointed former Teva senior VP Dr Maurice Chagnaud as president of its European business and head of inhalation strategy.

Dr Chagnaud will be based at the company's operations in Schaffhausen, Switzerland, where he will be responsible for Lupin's business strategy in Europe, including Russia and the CIS countries.

He will also be responsible for developing Lupin's core strategy for inhalation across all developed markets.

Prior to joining Lupin, Dr Chagnaud was senior VP, Central and Eastern Europe, at Israel-based Teva. He was with Teva for just under seven years, with other roles include chief commercial officer in Europe and CEO of the company's operations in France.

In addition, Dr Chagnaud's industry experience also includes time as general manager for Merck KGaA'a generics business in Italy.

20th February 2014

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics